T cell receptor beta variable 19Genealiases: TCRBV17S1A1T · TCRBV19S1
Q-omics provides the consensus-scored TRBV19 profile across patient tissues and cancer cell-line models. TRBV19 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRBV19 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, TRBV19 RNA expression shows 15,910 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where TRBV19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRBV19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRBV19 survival associations across molecular data types. TRBV19 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRBV19 RNA expression–survival associations across cancer types. High TRBV19 expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, CESC, LUAD and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRBV19 RNA expression.
This table summarizes TRBV19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TRBV19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRBV19 shows lower tumor expression in COAD, LUSC, THCA and UCEC and higher tumor expression in KIRC and BRCA. The COAD box plot shows higher TRBV19 RNA expression in normal versus tumor tissue (log2 FC = −1.408, t-test p < 0.001).
This table shows molecular features associated with TRBV19 in patient tissues and cancer cell lines. In patient samples, TRBV19 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRBV19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC.
